NASDAQ:HRTS Tema Cardiovascular and Metabolics ETF (HRTS) Price, Holdings, & News $31.33 +0.56 (+1.82%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsShort InterestTrends About Tema Cardiovascular and Metabolics ETF (NASDAQ:HRTS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HRTS alerts:Sign Up Key Stats Today's Range$30.60▼$31.3850-Day Range$30.39▼$35.3452-Week Range$26.38▼$36.03Volume8,783 shsAverage Volume23,482 shsMarket Capitalization$77.70 millionAssets Under Management$76.38 millionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF OverviewThe Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.Read More… I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Tema Cardiovascular and Metabolics ETF ExpensesTypeHRTSTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.55%0.50%0.52%Other Expenses0.00%0.57%0.49%0.41%0.53%Total Expense0.99%0.72%0.71%0.63%0.71%Fee Waiver-0.24%-0.73%-0.52%-0.32%-0.57%Net Expense0.75%0.60%0.61%0.56%0.59% Receive HRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Cardiovascular and Metabolics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address HRTS ETF News HeadlinesHRT may help to protect the heartOctober 22, 2024 | dailymail.co.ukInvesting in Real Assets: The Growing Demand and Opportunity with Brompton’s BREA ETFOctober 10, 2024 | theglobeandmail.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 23, 2024 | DTI (Ad)Oil Prices Spike Amid Middle East TensionsOctober 8, 2024 | theglobeandmail.comGuardian Capital LP Launches Two New ETFs on CBOE CanadaOctober 8, 2024 | theglobeandmail.comHigh temperatures and factors such as obesity ‘driving global rises in stroke’September 18, 2024 | msn.comSee More Headlines HRTS ETF - Frequently Asked Questions How have HRTS shares performed this year? Tema Cardiovascular and Metabolics ETF's stock was trading at $30.61 at the start of the year. Since then, HRTS shares have increased by 2.4% and is now trading at $31.33. View the best growth stocks for 2024 here. Who are Tema Cardiovascular and Metabolics ETF's major shareholders? Tema Cardiovascular and Metabolics ETF's top institutional investors include Sterling Investment Advisors Ltd. (6.40%). How do I buy shares of Tema Cardiovascular and Metabolics ETF? Shares of HRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Tema Cardiovascular and Metabolics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tema Cardiovascular and Metabolics ETF investors own include Scilex (SCLX), Rigetti Computing (RGTI), Pfizer (PFE), BlackBerry (BB), Butterfly Network (BFLY), BioNTech (BNTX) and Barrick Gold (GOLD). Fund Details IssuerTema Global Fund NameTema Cardiovascular and Metabolics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:HRTS Inception Date11/20/2023 Fund ManagerDavid Song, Yuri Khodjamirian Previous SymbolNASDAQ:HRTS WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings45 Fund Statistics Assets Under Management$76.38 million Average Daily Volume$0.00 Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest500 shs Miscellaneous Outstanding Shares2,480,000Beta0.93 Creation Unit10,000 Creation Fee$500.00 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 HRTS HoldingsAmgen (NASDAQ:AMGN)Holding Weight: 7.92%Eli Lilly and Company (NYSE:LLY)Holding Weight: 5.49%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 5.29%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.97%Chugai Pharmaceutical Co., Ltd.Holding Weight: 3.93%Novo Nordisk A/SHolding Weight: 3.75%Crinetics Pharmaceuticals (NASDAQ:CRNX)Holding Weight: 3.66%BridgeBio Pharma (NASDAQ:BBIO)Holding Weight: 3.63%AstraZeneca PLCHolding Weight: 3.46%Cytokinetics (NASDAQ:CYTK)Holding Weight: 3.16%Full Holdings DetailsHRTS Sector ExposureHRTS Industry Exposure This page (NASDAQ:HRTS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
